glp-1 medication pregnancy safety Navigating and Pregnancy: Insights, Safety, and Postpartum Considerations Weight, metabolism and fertility are

Langmesser S, Albrecht U

In order to avoid exposure to ionizing radiation, various other scanning methods (e.g., optical and white-light scanning) have been explored for quantification of deformity and to follow the results of non-operative management in these conditions

Results: After the surgery, VSG mice displayed reduced body weight (Sham:43.70.8;VSG:37.70.8,g) and perigonadal fat pad (Sham:4.80.2;VSG:2.10.3,% body weight), which probably contributed to lower fasting glycemia (Sham:129.14.1;VSG:101.84.9,mg/dL) and insulinemia (Sham:2.20.3;VSG:0.90.1,ng/mL), improve insulin sensitivity (Sham:156881.9;VSG:101542.7,AUC) and glucose tolerance (Sham:381541603;VSG:275361907,AUC), in addition to lower insulin secretion (Sham:1.50.10;VSG:0.60.03,ng/islet.h) in these mice compared to Sham mice

It has shown strong phase 2 results and promising topline phase 3 results, but it is not yet an approved medication

Tirzepatide is a GLP-1 + GIP dual-action agonist

A commitment to science-based, pure products